StockNews.com Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

Research analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report released on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

Shares of Titan Pharmaceuticals stock opened at $3.75 on Friday. Titan Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $14.80. The company has a fifty day moving average of $3.72 and a 200-day moving average of $3.71. The stock has a market capitalization of $3.43 million, a price-to-earnings ratio of -0.72 and a beta of 1.27.

Titan Pharmaceuticals (NASDAQ:TTNP) last posted its quarterly earnings results on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.